173 related articles for article (PubMed ID: 36120818)
21. Obesity Without Metabolic Abnormality and Incident CKD: A Population-Based British Cohort Study.
Wang J; Niratharakumar K; Gokhale K; Tahrani AA; Taverner T; Thomas GN; Dasgupta I
Am J Kidney Dis; 2022 Jan; 79(1):24-35.e1. PubMed ID: 34146618
[TBL] [Abstract][Full Text] [Related]
22. Effects of low-fat compared with high-fat diet on cardiometabolic indicators in people with overweight and obesity without overt metabolic disturbance: a systematic review and meta-analysis of randomised controlled trials.
Lu M; Wan Y; Yang B; Huggins CE; Li D
Br J Nutr; 2018 Jan; 119(1):96-108. PubMed ID: 29212558
[TBL] [Abstract][Full Text] [Related]
23. Metabolically unhealthy phenotype in normal weight population and risk of mortality and major adverse cardiac events: A meta-analysis of 41 prospective cohort studies.
Putra ICS; Kamarullah W; Prameswari HS; Pramudyo M; Iqbal M; Achmad C; Akbar MR; Tiksnadi BB
Diabetes Metab Syndr; 2022 Oct; 16(10):102635. PubMed ID: 36240685
[TBL] [Abstract][Full Text] [Related]
24. Metabolic obesity phenotypes and chronic kidney disease: a cross-sectional study from the RaNCD cohort study.
Jam SA; Moloudpour B; Najafi F; Darbandi M; Pasdar Y
BMC Nephrol; 2022 Jul; 23(1):233. PubMed ID: 35778682
[TBL] [Abstract][Full Text] [Related]
25. Risk of hypertension among different metabolic phenotypes: a systematic review and meta-analysis of prospective cohort studies.
Mirzababaei A; Mozaffari H; Shab-Bidar S; Milajerdi A; Djafarian K
J Hum Hypertens; 2019 May; 33(5):365-377. PubMed ID: 30568291
[TBL] [Abstract][Full Text] [Related]
26. Obesity Metabolic Phenotype, Changes in Time and Risk of Diabetes Mellitus in an Observational Prospective Study on General Population.
Yang C; Liu X; Dang Y; Li J; Jing J; Tian D; Qiu J; Zhang J; Yan N; Liu X; Zhao Y; Zhang Y
Int J Public Health; 2022; 67():1604986. PubMed ID: 36250153
[No Abstract] [Full Text] [Related]
27. Metabolically healthy overweight/obesity and cancer risk: A representative cohort study in Taiwan.
Lin CJ; Chang YC; Hsu HY; Tsai MC; Hsu LY; Hwang LC; Chien KL; Yeh TL
Obes Res Clin Pract; 2021; 15(6):564-569. PubMed ID: 34782258
[TBL] [Abstract][Full Text] [Related]
28. Metabolic dysfunction, rather than obesity, is a risk factor for chronic kidney disease in Chinese population.
Yang S; Ling J; Zhang S; Li Y; Yang G
Aging Male; 2024 Dec; 27(1):2335158. PubMed ID: 38600669
[TBL] [Abstract][Full Text] [Related]
29. The Metabolic Profiles of Metabolically Healthy Obese and Metabolically Unhealthy Obese South African Adults over 10 Years.
Kruger HS; De Lange-Loots Z; Kruger IM; Pieters M
Int J Environ Res Public Health; 2022 Apr; 19(9):. PubMed ID: 35564455
[TBL] [Abstract][Full Text] [Related]
30. Metabolically Healthy Obesity and Ischemic Heart Disease: A 10-Year Follow-Up of the Inter99 Study.
Hansen L; Netterstrøm MK; Johansen NB; Rønn PF; Vistisen D; Husemoen LLN; Jørgensen ME; Rod NH; Færch K
J Clin Endocrinol Metab; 2017 Jun; 102(6):1934-1942. PubMed ID: 28323999
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Prognosis of Acute Myocardial Infarction Associated With Metabolic Health and Obesity Status.
Chew NWS; Kong G; Venisha S; Chin YH; Ng CH; Muthiah M; Khoo CM; Chai P; Kong W; Poh KK; Foo R; Yeo TC; Chan MY; Loh PH
Endocr Pract; 2022 Aug; 28(8):802-810. PubMed ID: 35654337
[TBL] [Abstract][Full Text] [Related]
32. Metabolically healthy and unhealthy weight statuses, health issues and related costs: Findings from the 2013-2015 European Health Examination Survey in Luxembourg.
Samouda H; Ruiz-Castell M; Karimi M; Bocquet V; Kuemmerle A; Chioti A; Dadoun F; Stranges S
Diabetes Metab; 2019 Apr; 45(2):140-151. PubMed ID: 29249613
[TBL] [Abstract][Full Text] [Related]
33. Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals.
Hashimoto Y; Hamaguchi M; Fukuda T; Ohbora A; Kojima T; Fukui M
Endocrine; 2017 Jul; 57(1):89-97. PubMed ID: 28508194
[TBL] [Abstract][Full Text] [Related]
34. Implications of metabolic health status and obesity on the risk of kidney cancer: A nationwide population-based cohort study.
Cho YK; Kim HS; Park JY; Lee WJ; Kim YJ; Jung CH
Front Endocrinol (Lausanne); 2022; 13():976056. PubMed ID: 36339433
[TBL] [Abstract][Full Text] [Related]
35. The association between transition from metabolically healthy obesity to metabolic syndrome, and incidence of cardiovascular disease: Tehran lipid and glucose study.
Hosseinpanah F; Tasdighi E; Barzin M; Mahdavi M; Ghanbarian A; Valizadeh M; Azizi F
PLoS One; 2020; 15(9):e0239164. PubMed ID: 32947607
[TBL] [Abstract][Full Text] [Related]
36. Metabolically healthy obese and unhealthy normal weight in Iranian adult population: Prevalence and the associated factors.
Hajian-Tilaki K; Heidari B
Diabetes Metab Syndr; 2018; 12(2):129-134. PubMed ID: 29196231
[TBL] [Abstract][Full Text] [Related]
37. Metabolically healthy obesity, transition to unhealthy phenotypes, and type 2 diabetes in 0.5 million Chinese adults: the China Kadoorie Biobank.
Song Z; Gao M; Lv J; Yu C; Guo Y; Bian Z; Wei Y; Yang L; Du H; Chen Y; Zhang J; Yao J; Chen J; Chen Z; Huang T; Li L;
Eur J Endocrinol; 2022 Jan; 186(2):233-244. PubMed ID: 34874895
[TBL] [Abstract][Full Text] [Related]
38. Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: a meta-analysis of prospective cohort studies.
Fan J; Song Y; Chen Y; Hui R; Zhang W
Int J Cardiol; 2013 Oct; 168(5):4761-8. PubMed ID: 23972953
[TBL] [Abstract][Full Text] [Related]
39. The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: A PRISMA-compliant article.
Lin H; Zhang L; Zheng R; Zheng Y
Medicine (Baltimore); 2017 Nov; 96(47):e8838. PubMed ID: 29381992
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular Risk Factors Associated With the Metabolically Healthy Obese (MHO) Phenotype Compared to the Metabolically Unhealthy Obese (MUO) Phenotype in Children.
Genovesi S; Antolini L; Orlando A; Gilardini L; Bertoli S; Giussani M; Invitti C; Nava E; Battaglino MG; Leone A; Valsecchi MG; Parati G
Front Endocrinol (Lausanne); 2020; 11():27. PubMed ID: 32117055
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
